June 16, 2017

Dohmen welcomes Lynda Parker, Chief Business Development Officer, Direct-to-Patient Services, DLSS

Dohmen has appointed Lynda Parker as its new Chief Business Development Officer, Direct-to-Patient Services for Dohmen Life Science Services. With more than 30 years of experience, she’s successfully led product commercialization and helped orphan drug manufacturers overcome the challenges faced in serving and providing ongoing support to the rare disease community.

 

“As a business process outsourcer, we are proud to have the industry’s best on our team – those who are passionate about our mission to better connect orphan drug manufacturers with their patients,” said Dan Johnson, President, DLSS. “Lynda has sat side-by-side many orphan drug manufacturers and understands the unique value we bring to the market – offering a wrap-around model which focuses on reducing the burden of the disease and increasing therapy adherence through coordinated care, patient education and comprehensive support.”

 

In her role at DLSS, Parker leads the sales and account management teams for Direct-to-Patient Services to provide clients services that build lasting relationships, grow economic value, ensure compliance and improve operational excellence.

 

"It is exciting to be a part of a company with such a patient-focused, values-driven purpose," Parker said. “We offer something the industry really needs, a better model for integrated outsourcing support that helps our clients focus on what’s really important, serving their rare disease patients.”

 

Parker has a Bachelor of Arts degree in economics from Lynchburg College in Virginia and attended the Aresty Executive Program at the Wharton Business School. She was also recognized as a Rising Star by the Healthcare Businesswoman’s Association and has earned countless awards for values-based leadership and sales excellence.